Liver Fibrosis in Some Patients with Non-Alcoholic Fatty Liver Disease: from Diagnosis to Prognosis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of this publication was to update knowledge about non-alcoholic fatty liver disease (NAFLD) and fibrogenesis, as well as factors that have a positive or negative prognostic value in relation to the formation and progression of liver fibrosis. This review article contains the current literature dates about pathogenetic factors of the development of liver fibrosis in NAFLD and conceptual ideas about its diagnosis at this moment. Obviously, along with genetic and epigenetic factors, hyper- and disproduction of organokines affect to the progression of the disease. Evaluation of the quantitative and qualitative composition of the microbiota, the integrity of the epithelial intestinal barrier are perceptual fields for research this problem. Non-invasive proprietary and non-proprietary scales for assessing the risk of steatosis and fibrosis, transient elastometry are suitable for routine assessment of individual risk of disease development and progression. This scientific review demonstrates proofs of necessity to develop individual strategies for the management of patients with NAFLD in relation to its metabolic activity and the stage of liver fibrosis.

Full Text

Restricted Access

About the authors

Tatyana S. Krolevets

Omsk State Medical University; Clinical Cardiology Dispensary

Author for correspondence.
Email: mts-8-90@mail.ru
ORCID iD: 0000-0002-7452-7230
SPIN-code: 8043-5634

MD, PhD, Associate Professor

Russian Federation, Omsk; Omsk

Maria A. Livzan

Omsk State Medical University

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6581-7017
SPIN-code: 1961-4082

MD, PhD, Professor

Russian Federation, Omsk

Maria I. Syrovenko

Omsk State Medical University; Clinical Cardiology Dispensary

Email: mariapli@yandex.ru
ORCID iD: 0000-0001-6300-367X
SPIN-code: 6428-7270

MD, PhD Student

Russian Federation, Omsk; Omsk

References

  1. Younossi ZM, Stepanova M, Rafiq N, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun. 2017;1(5):421–428. doi: https://doi.org/10.1002/hep4.1054
  2. Peleg N, Sneh Arbib O, Issachar A, et al. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS One. 2018;13(8):e0202393. doi: https://doi.org/10.1371/journal.pone.0202393
  3. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. doi: https://doi.org/10.1002/hep.29085
  4. Тимакова А.Ю., Скирденко Ю.П., Ливзан М.А., и др. Кардиоваскулярная коморбидность при неалкогольной жировой болезни печени // Экспериментальная и клиническая гастроэнтерология. — 2020. — № 10. — С. 88–95. [Timakova AYu, Skirdenko YuP, Livzan MA, et al. Cardiovascular comorbidity in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;10:88–95. (In Russ.)] doi: https://doi.org/10.31146/1682-8658-ecg-182-10-88-95]
  5. Маевская М.В., Котовская Ю.В., Ивашкин В.Т., и др. Национальный консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями // Терапевтический архив. — 2022. — Т. 94. — № 2. — С. 216–253. [Maevskaya MV, Kotovskaya YuV, Ivashkin VT, et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2):216–253. (In Russ.)] doi: https://doi.org/10.26442/00403660.2022.02.201363
  6. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2016. — Т. 26. — № 2. — С. 24–42. [Ivashkin VT, Mayevskaya MV, Pavlov CS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24–42. (In Russ.)] doi: https://doi.org/10.22416/1382-4376-2016-26-2-24-42
  7. Лазебник Л.Б. Steatotic liver disease — стеатозная болезнь печени — международная трактовка понятия «зонтика» для всех заболеваний печеночной паренхимы // Экспериментальная и клиническая гастроэнтерология. — 2023. — Т. 216. — № 8. — С. 24–26. [Lazebnik LB. Steatotic liver disease — an international interpretation of the concept an “umbrella” for all diseases of the hepatic parenchyma. Experimental and Clinical Gastroenterology. 2023;216(8): 24–26. (In Russ.)] doi: https://doi.org/10.31146/1682-8658-ecg-216-8-24-26
  8. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. doi: https://doi.org/10.1016/j.cgh.2021.12.002
  9. Евстифеева С.Е., Шальнова С.А., Куценко В.А., и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2) // Кардио-васкулярная терапия и профилактика. — 2022. — Т. 21. — № 9. — С. 3356. [Evstifeeva SE, Shalnova SA, Kutsenko VA, et al. Prevalence of non-alcoholic fatty liver disease in the working-age population: association with socio-demographic indicators and behavioral risk factors (data from ESSE-RF-2) Cardiovascular therapy and prevention. 2022; 21(9):3356. (In Russ.)] doi: https://doi.org/10.15829/1728-8800-2022-3356
  10. Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2016. — Т. 25. — № 6. — С. 31–41. [Ivashkin VT, Drapkina OM, Maev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients in the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;25(6):31–41. (In Russ.)]
  11. World Health Organization — WHO (2017). Obesity and overweight. Controlling the global obesity epidemic. Available from: http://www.who.int/nutrition/topics/obesity/en (accessed: 12.10.2017).
  12. Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27–42. doi: https://doi.org/10.1111/j.1467-789x.2004.00126.x
  13. Самородская И.В. Новая парадигма ожирения // Проблемы эндокринологии. — 2014. — Т. 60. — № 5. — С. 43–48. [Samorodskaia IV. The new paradigm of obesity. Problemy Endokrinologii. 2014;60(5):43–48. (In Russ.)] doi: https://doi.org/10.14341/probl201460543-48
  14. Chan WK. Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S58–S67. doi: https://doi.org/10.3350/cmh.2022.0350
  15. Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol. 2015;21(39):11088–11111. doi: https://doi.org/10.3748/wjg.v21.i39.11088
  16. Francisco V, Sanz MJ, Real JT, et al. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets? Biology (Basel). 2022;11(8):1237. doi: https://doi.org/10.3390/ biology11081237
  17. Francisco V, Pino J, Campos-Cabaleiro V, et al. Obesity, Fat Mass and Immune System: Role for Leptin. Front Physiol. 2018;9:640. doi: https://doi.org/10.3389/fphys.2018.00640
  18. Hejlova I, Honsova E, Sticova E, et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22(5):644–655. doi: https://doi.org/10.1002/lt.24393
  19. Jiménez-Cortegana C, García-Galey A, Tami M, et al. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines. 2021;9(7):762. doi: https://doi.org/10.3390/biomedicines9070762
  20. Nguyen TMD. Adiponectin: Role in Physiology and Pathophysiology. Int J Prev Med. 2020;11:136. doi: https://doi.org/10.4103/ijpvm.IJPVM_193_20
  21. Heydari M, Cornide-Petronio ME, Jiménez-Castro MB, et al. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases? Int J Mol Sci. 2020;21(15):5242. doi: https://doi.org/10.3390/ijms21155242
  22. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016;61(8):2389–2396. doi: https://doi.org/10.1007/s10620-016-4125-2
  23. Chen Y, Wu S, Tian Y. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98(1):7–14. doi: https://doi.org/10.1038/labinvest.2017.95
  24. Черкащенко Н.А., Ливзан М.А., Кролевец Т.С. Клинические проявления коморбидного течения желчнокаменной болезни и неалкогольной жировой болезни печени // Терапевтический архив. — 2020. — Т. 92. — № 8. — C. 29–36. [Cherkashchenko NA, Livzan MA, Krolevets TS. Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease. Terapevticheskii Arkhiv. 2020;92(8):29–36. (In Russ.)] doi: https://doi.org/10.26442/00403660.2020.08.000764
  25. Черкащенко Н.А., Ливзан М.А., Кролевец Т.С., и др. Система поддержки врачебных решений по прогнозу метаболических рисков у больных с коморбидным течением неалкогольной жировой болезни печени и желчнокаменной болезни после холецистэктомии // Медицинский алфавит. — 2020. — Т. 1. — № 30. — С. 11–17. [Cherkashchenko NA, Livzan MA, Krolevets TS, et al. Decision support system for predicting metabolic risks in patients with comorbid non-alcoholic fatty liver disease and gallstone disease after cholecystectomy. Medical Alphabet. 2020;1(30):11–17. (In Russ.)] doi: https://doi.org/10.33667/2078-5631-2020-30-11-17
  26. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении // Терапевтический архив. — 2017. — Т. 89. — № 1. — С. 128–133. [Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Terapevticheskii Arkhiv. 2017;89(1):128–133. (In Russ.)] doi: https://doi.org/10.17116/terarkh2017891128-133
  27. Méndez-Sánchez N, Ponciano-Rodrigoez G, Chavez-Tapia N, et al. Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(2):203–208. doi: https://doi.org/10.2174/1568008054064896
  28. Saraç S, Atamer A, Atamer Y, et al. Leptin levels and lipoprotein profiles in patients with cholelithiasis. J Int Med Res. 2015;43(3):385–392. doi: https://doi.org/10.1177/0300060514561134
  29. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59(3):550–556. doi: https://doi.org/10.1016/j.jhep.2013.04.027
  30. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.e1–9. doi: https://doi.org/10.1016/j.cgh.2014.04.014
  31. Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. doi: https://doi.org/10.3748/wjg.v23.i47.8263
  32. Le P, Payne JY, Zhang L, et al. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies. Clin Gastroenterol Hepatol. 2023;21(5):1154–1168. doi: https://doi.org/10.1016/j.cgh.2022.07.033
  33. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J Hepatol. 2021;75(3):659–689. doi: https://doi.org/10.1016/j.jhep.2021.05.025
  34. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–1457. doi: https://doi.org/10.1016/j.hep.2003.09.022
  35. Ливзан М.А., Ахмедов В.А., Кролевец Т.С. и др. Информативность неинвазивных маркеров фиброза печени у пациентов с неалкогольной жировой болезнью печени // Терапевтический архив. — 2016. — Т. 88. — № 12. — С. 62–68. [Livzan MA, Akhmedov VA, Korolevets TS, et al. The informative value of noinvasive liver fibrosis markers in patients with nonalcoholic fatty liver disease. Terapevticheskii Arkhiv. 2016;88(12):62–68. (In Russ.)] doi: https://doi.org/10.17116/terarkh2016881262-68
  36. Кролевец Т.С., Ливзан М.А., Чебаненко Е.В., и др. Прогностическая модель неинвазивной оценки формирования и прогрессирования фиброза печени у пациентов с неалкогольной жировой болезнью печени // Современные проблемы науки и образования. — 2018. — № 3. [Krolevec TS, Livzan MA, CHebanenko EV, i dr. Prognosticheskaya model’ neinvazivnoj ocenki formirovaniya i progressirovaniya fibroza pecheni u pacientov s nealkogol’noj zhirovoj bolezn’yu pecheni. Sovremennye problemy nauki i obrazovaniya. 2018;3. (In Russ.)]. Available from: https://science-education.ru/ru/article/view?id=27713 (accessed: 31.05.2023)
  37. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–15723. doi: https://doi.org/10.1073/pnas.0407076101
  38. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. doi: https://doi.org/10.1038/nature11450
  39. Ding L, Chang M, Guo Y, et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis. 2018;17(1):286. doi: https://doi.org/10.1186/s12944-018-0939-6
  40. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887. doi: https://doi.org/10.1002/hep.22848
  41. Ohlsson B, Orho-Melander M, Nilsson PM. Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations. Int J Mol Sci. 2017;18(3):582. doi: https://doi.org/10.3390/ijms18030582
  42. Cho YE, Kim DK, Seo W, et al. Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. Hepatology. 2021;73(6):2180–2195. doi: https://doi.org/10.1002/hep.30652
  43. Kaushal K, Agarwal S, Sharma S, et al. Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study. J Clin Exp Hepatol. 2022;12(4):1102–1113. doi: https://doi.org/10.1016/j.jceh.2022.01.006
  44. Кролевец Т.С., Ливзан М.А., Сыровенко М.И. Фиброз печени при неалкогольной жировой болезни печени: роль адипокинов и неинвазивной оценки состояния кишечного барьера // Доказательная гастроэнтерология. — 2023. — Т. 12. — № 2. — С. 51–59. [Krolevets TS, Livzan MA, Syrovenko MI. Liver fibrosis in nonalcoholic fatty liver disease: the role of adipokines and noninvasive assessment of the intestinal barrier. Russian Journal of Evidence-based Gastroenterology = Dokazatel’naya gastroenterologiya. 2023;12(2):51–59. (In Russ.)] doi: https://doi.org/10.17116/dokgastro20231202151

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies